Questions regarding the visit plan for 2228.HK:

$XTALPI(02228.HK) Organized the questions raised by community friends, roughly as follows:

Part One: Industry Status and Company Positioning

1. Industry Status and Differentiation:

• What is the overall status of the AI pharmaceutical industry currently? What is JingTai's core competitive advantage in this industry?

1. China-U.S. Gap:

• Does the company believe there is a gap between China and the U.S. in the field of AI pharmaceuticals? If so, what are the main aspects of this gap (such as algorithms, data quality, application scenarios, etc.)?

1. Future Development Direction:

• What are the company's future focuses in the field of AI drug development? Will it concentrate on specific disease areas or types of drugs?

• Besides drug development, will the company explore other application areas (such as materials, agriculture, etc.)?

Part Two: Technology and Commercialization

1. Technical Capability and Moat:

• Has JingTai developed AI algorithms with independent intellectual property rights? What advantages do these algorithms have in handling complex molecular structures and biological processes?

• What are the company's core technologies and moat? How does the company prove the value of its moat to the market based on the current valuation?

1. Successful AI Cases:

• Can you share some specific cases where JingTai successfully shortened the drug development cycle using AI technology? How much time was shortened, and how much cost was saved?

1. Business Model and Cooperation:

• How has the company's business model evolved? Will it consider establishing closer partnerships with large pharmaceutical companies in the future?

Part Three: Financial Status and Operational Capability

1. Financial Performance and Profitability:

• The company's operating revenue for 2024 is 111 million yuan, but the net profit loss reaches 1.335 billion yuan. How does the company view this gap? How will it improve its income and expenditure structure in the future?

1. Trading Financial Assets:

• The company has 1.7 billion yuan in trading financial assets. As a technology company primarily focused on drug development, what are the specific uses and strategic intentions of this asset?

1. Cash Flow and Self-Recovery:

• In the face of significant losses, how does the company ensure that its cash flow supports operations? What is the company's expectation for the timing of achieving self-recovery?

Part Four: Future Outlook and Investor Concerns

1. Industry Outlook and Investment Logic:

• What is the core logical framework of the AI pharmaceutical industry? Can it truly shorten drug development time and promote commercialization?

• Regarding the company's potential to build an AI platform to cover other fields, how does the company view this strategic direction? 11. Investment Returns:

• For potential investors, how does the company plan its future profit path? What are the main ways the company will achieve revenue?

Other Additional Questions (if time permits)

1. Adjusting Expectations:

• Will the company adjust its expectations or investments in AI drug development based on industry trends?

1. Product Commercialization:

• What is the current progress of the company's product commercialization? Are there any representative products that have been launched or are about to be launched?